Nulojix and Atrial fibrillation aggravated - a phase IV clinical study of FDA data


Atrial fibrillation aggravated is found among people who take Nulojix, especially for people who are male, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Nulojix and have Atrial fibrillation aggravated. It is created by eHealthMe based on reports of 1,561 people who have side effects when taking Nulojix from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2022

1,561 people reported to have side effects when taking Nulojix.
Among them, 8 people (0.51%) have Atrial fibrillation aggravated.

What is Nulojix?

Nulojix has active ingredients of belatacept. eHealthMe is studying from 1,562 Nulojix users for its effectiveness, alternative drugs and more.

What is Atrial fibrillation aggravated?

Atrial fibrillation aggravated (serious fibrillation of the muscles of the atria of the heart) is found to be associated with 1,482 drugs and 669 conditions by eHealthMe.

Number of Nulojix and Atrial fibrillation aggravated reports submitted per year:

Could Nulojix cause Atrial fibrillation aggravated?

Time on Nulojix when people have Atrial fibrillation aggravated *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Atrial fibrillation aggravated when taking Nulojix *:

  • female: 37.5 %
  • male: 62.5 %

Age of people who have Atrial fibrillation aggravated when taking Nulojix *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Nulojix *:

  1. Bactrim: 3 people, 37.50%
  2. Eliquis: 3 people, 37.50%
  3. Lantus: 3 people, 37.50%
  4. Amlodipine: 2 people, 25.00%
  5. Aranesp: 2 people, 25.00%
  6. Potassium: 2 people, 25.00%
  7. Paracetamol: 2 people, 25.00%
  8. Novorapid: 2 people, 25.00%
  9. Eupressyl: 2 people, 25.00%
  10. Prograf: 2 people, 25.00%

Common side effects people have besides Atrial fibrillation aggravated *:

  1. Hereditary Fructose Intolerance: 2 people, 25.00%
  2. Breathing Difficulty: 2 people, 25.00%
  3. Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 2 people, 25.00%
  4. Colitis (inflammation of colon): 2 people, 25.00%
  5. Diabetes Mellitus Inadequate Control: 2 people, 25.00%
  6. Mitral Valve Incompetence (inefficient heart valve): 2 people, 25.00%
  7. Lymphocele (a collection of lymphatic fluid within the body not bordered by epithelial lining): 2 people, 25.00%
  8. Hepatocellular Injury (liver injury): 2 people, 25.00%
  9. Urinary Tract Infection: 2 people, 25.00%
  10. Weakness: 1 person, 12.50%

Common conditions people have *:

  1. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 25.00%
  2. High Blood Pressure: 2 people, 25.00%
  3. Drug Intolerance (drug sensitivity): 2 people, 25.00%
  4. Platelet Aggregation Inhibition: 1 person, 12.50%
  5. Kidney Transplant Rejection: 1 person, 12.50%
  6. Immunodeficiency Disorders: 1 person, 12.50%
  7. Hyperthyroidism (over activity of the thyroid gland): 1 person, 12.50%
  8. Fluid Overload (too much fluid in the blood): 1 person, 12.50%
  9. Diabetes: 1 person, 12.50%
  10. Cardiomyopathy (weakening of the heart muscle): 1 person, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Nulojix and have Atrial fibrillation aggravated?

Check whether Atrial fibrillation aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Atrial fibrillation aggravated and when was it recovered:

Expand to all the drugs that have ingredients of belatacept:

Alternative drugs to, pros and cons of Nulojix:

Atrial fibrillation aggravated treatments and more:

COVID vaccines that are related to Atrial fibrillation aggravated:

Common drugs associated with Atrial fibrillation aggravated:

All the drugs that are associated with Atrial fibrillation aggravated:

Common conditions associated with Atrial fibrillation aggravated:

All the conditions that are associated with Atrial fibrillation aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on belatacept (the active ingredients of Nulojix) and Nulojix (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: